GlassScriptPhysician profile
Yoon Sung Min
NPI 1871695346
$25,142.01
in general payments reported to CMS, 2019-2025
45 companies · $2,556 in 2025
The $2,556 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,960 · 2020: $3,974 · 2021: $2,895 · 2022: $3,690 · 2023: $4,004 · 2024: $4,064 · 2025: $2,556.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $9.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,613.45 |
| Education | $9.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $5,180.22 | 2019-2025 | Enbrel, Evenity, Otezla |
| Abbvie INC. | $2,147.17 | 2019-2025 | |
| Horizon Therapeutics Plc | $2,078.64 | 2019-2023 | Krystexxa |
| Janssen Biotech, INC. | $1,780.44 | 2019-2025 | Tremfya, Simponi Aria |
| Mallinckrodt Hospital Products INC. | $1,542.86 | 2020-2025 | Acthar |
| Astrazeneca Pharmaceuticals LP | $1,502.86 | 2021-2025 | Saphnelo |
| Novartis Pharmaceuticals Corporation | $1,151.37 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $996.80 | 2019-2025 | Strensiq |
| Lilly USA, LLC | $916.51 | 2019-2024 | Taltz |
| Radius Health, INC. | $856.65 | 2019-2025 | Tymlos |
| Glaxosmithkline, LLC. | $823.42 | 2019-2025 | Benlysta |
| Ucb, INC. | $797.68 | 2021-2025 | Cimzia, Bimzelx |
| Ani Pharmaceuticals, INC. | $787.98 | 2022-2025 | Purified Cortrophin Gel, Sovuna |
| Pfizer INC. | $620.11 | 2019-2025 | |
| Genzyme Corporation | $606.65 | 2019-2021 |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $574.31 | 2019-2025 | Orencia |
| Fresenius Kabi USA, LLC | $414.76 | 2023-2025 | Idacio, Adalimumab-Aacf |
| Celgene Corporation | $359.04 | 2019 | |
| Mallinckrodt Enterprises LLC | $238.42 | 2019 | |
| Sobi, INC | $222.02 | 2021-2025 | |
| US Oncology Corporate, INC. | $191.96 | 2024 | |
| Janssen Scientific Affairs, LLC | $161.94 | 2019-2022 | |
| Genentech USA, INC. | $152.59 | 2019-2025 | Actemra |
| Depuy Synthes Sales INC. | $104.24 | 2021-2024 | Monovisc, Orthovisc |
| Collegium Pharmaceutical, INC. | $102.51 | 2023 | Belbuca, Xtampza |
| Bioventus LLC | $100.16 | 2019-2025 | Supartz Fx Sodium Hyaluronate |
| Medexus Pharma, INC. | $82.39 | 2019 | |
| Octapharma USA, INC. | $79.39 | 2022-2024 | Octagam Immune Globulin (Human) |
| Aurinia Pharma U.S., INC. | $74.86 | 2021-2024 | Lupkynis |
| Fidia Pharma USA INC. | $73.90 | 2022-2024 | Hymovis, Triluron, Hyalgan |
| Kiniksa Pharmaceuticals, LTD. | $67.17 | 2022-2023 | Arcalyst |
| Ultragenyx Pharmaceutical INC. | $59.45 | 2021-2024 | Crysvita |
| Sanofi-Aventis U.S. LLC | $37.65 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.13 | 2020 | |
| Pacira Therapeutics, INC. | $28.38 | 2019 | |
| Orthogenrx INC. | $25.84 | 2020 | |
| Tonix Medicines, INC. | $23.57 | 2025 | Tonmya |
| Daiichi Sankyo INC. | $23.03 | 2021 | |
| Zimmer Biomet Holdings, INC. | $22.93 | 2019 | |
| Werfen USA LLC | $20.73 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $18.67 | 2024 | Truxima |
| Avanos Medical | $17.43 | 2023 | Trivisc Sodium Hyaluronate |
| Scilex Pharmaceuticals INC. | $14.58 | 2024 | |
| Zyla Life Sciences, INC. | $14.52 | 2019 | |
| Boston Scientific Corporation | $11.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yoon Min listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.